MedPath

Immodulon Therapeutics Ltd.

Immodulon Therapeutics Ltd. logo
🇬🇧United Kingdom
Ownership
Subsidiary
Employees
11
Market Cap
-
Website
http://www.immodulon.com

Clinical Trials

10

Active:4
Completed:4

Trial Phases

2 Phases

Phase 1:6
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (66.7%)
Phase 2
3 (33.3%)

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
First Posted Date
2018-10-18
Last Posted Date
2024-04-29
Lead Sponsor
Immodulon Therapeutics Ltd
Target Recruit Count
16
Registration Number
NCT03711188
Locations
🇬🇧

St George's University Hospitals NHS Foundation Trust, London, United Kingdom

🇬🇧

The Christie Hospital, Manchester, United Kingdom

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

First Posted Date
2017-01-04
Last Posted Date
2024-11-25
Lead Sponsor
Immodulon Therapeutics Ltd
Target Recruit Count
2
Registration Number
NCT03009058
Locations
🇫🇷

Centre Léon Bérard, Dpt Medecine & INSERM, Lyon, France

🇫🇷

Gustave Roussy Cancer Center, Villejuif, France

🇬🇧

St George's University of London, Institute of Infection and Immunity, London, United Kingdom

and more 1 locations

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Phase 1
Terminated
Conditions
Malignant Melanoma
First Posted Date
2012-03-21
Last Posted Date
2023-06-22
Lead Sponsor
Immodulon Therapeutics Ltd
Target Recruit Count
10
Registration Number
NCT01559818
Locations
🇬🇧

St Georges University of London, London, United Kingdom

A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer

Phase 2
Completed
Conditions
Metastatic Colorectal Cancer
Interventions
First Posted Date
2012-02-28
Last Posted Date
2024-11-25
Lead Sponsor
Immodulon Therapeutics Ltd
Target Recruit Count
12
Registration Number
NCT01539824
Locations
🇬🇧

HCA International, The Sarah Cannon Research Institute, London, United Kingdom

🇬🇧

The London Clinic, London, United Kingdom

A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

Phase 1
Completed
Conditions
Melanoma
First Posted Date
2011-03-04
Last Posted Date
2012-12-06
Lead Sponsor
Immodulon Therapeutics Ltd
Target Recruit Count
19
Registration Number
NCT01308762
Locations
🇬🇧

HCA Clinical Trials Unit, 79 Harley Street,, London, United Kingdom

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.